OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
PLRZ$15.7755

Polyrizon Ltd

Biotechnology & Medical ResearchVerified

Polyrizon maintains a strong liquidity position, with a current ratio of 29.03, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to $1.3 million, and it has no long-term debt, contributing to a debt-to-equity ratio of 0.0. The price-to-book ratio of 1.34 suggests that the market values the company slightly above its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset premium. The company's profitability metrics are negative, with a return on equity of -15.89% and a return on assets of -15.56%, reflecting a loss-making position. The operating income and net income are -$6.25 million and -$3.34 million, respectively, indicating a challenging financial performance. The EV/EBITDA ratio of -4.29 further underscores the company's unprofitability and the market's cautious valuation. Polyrizon's revenue concentration and geographic exposure are not explicitly detailed in the available data, but the absence of disclosed segments suggests a potentially undiversified business model. The company's operations are likely concentrated in a single therapeutic area or geographic region, which could pose concentration risks. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The operating cash flow of -$4.53 million and free cash flow of -$3.0 million indicate a cash outflow, which could constrain future growth initiatives. The capital expenditure of -$7,000 is minimal, suggesting limited investment in expansion or new projects. Risk factors for Polyrizon include the potential for dilution, although the risk is currently assessed as low. The company has no immediate filing-based liquidity or dilution flags, and the valuation adjustments do not indicate significant dilution pressures. However, the negative profitability metrics and cash outflows highlight operational risks that could affect long-term stability. Recent events and filings do not show any significant developments that would impact the company's financial position or strategic direction. The absence of recent major events suggests a stable but stagnant operational environment.

30-day price · PLRZ(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyPolyrizon Ltd
TickerPLRZ.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Polyrizon Ltd is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of innovative therapies.

Classification. Polyrizon is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Polyrizon maintains a strong liquidity position, with a current ratio of 29.03, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to $1.3 million, and it has no long-term debt, contributing to a debt-to-equity ratio of 0.0. The price-to-book ratio of 1.34 suggests that the market values the company slightly above its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset premium. The company's profitability metrics are negative, with a return on equity of -15.89% and a return on assets of -15.56%, reflecting a loss-making position. The operating income and net income are -$6.25 million and -$3.34 million, respectively, indicating a challenging financial performance. The EV/EBITDA ratio of -4.29 further underscores the company's unprofitability and the market's cautious valuation. Polyrizon's revenue concentration and geographic exposure are not explicitly detailed in the available data, but the absence of disclosed segments suggests a potentially undiversified business model. The company's operations are likely concentrated in a single therapeutic area or geographic region, which could pose concentration risks. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The operating cash flow of -$4.53 million and free cash flow of -$3.0 million indicate a cash outflow, which could constrain future growth initiatives. The capital expenditure of -$7,000 is minimal, suggesting limited investment in expansion or new projects. Risk factors for Polyrizon include the potential for dilution, although the risk is currently assessed as low. The company has no immediate filing-based liquidity or dilution flags, and the valuation adjustments do not indicate significant dilution pressures. However, the negative profitability metrics and cash outflows highlight operational risks that could affect long-term stability. Recent events and filings do not show any significant developments that would impact the company's financial position or strategic direction. The absence of recent major events suggests a stable but stagnant operational environment.
Key takeaways
  • Polyrizon has a strong liquidity position with a current ratio of 29.03 and no long-term debt.
  • The company is currently unprofitable, with a return on equity of -15.89% and a return on assets of -15.56%.
  • The EV/EBITDA ratio of -4.29 reflects the market's cautious valuation of the company's unprofitable operations.
  • The company's revenue concentration and geographic exposure are not explicitly detailed, suggesting potential diversification risks.
  • The absence of immediate liquidity or dilution flags indicates a low near-term risk of capital structure changes.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income-$6.2M
Net income-$3.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$4.5M
CapEx-$7.0k
Free cash flow-$3.0M
Total assets$21.4M
Total liabilities$443.0k
Total equity$21.0M
Cash & equivalents$1.3M
Long-term debt$0.00
Valuation
Market price$15.77
Market cap$28.1M
Enterprise value$26.8M
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B1.3
P/Tangible book1.3
Tangible book$21.0M
Net cash$1.3M
Current ratio29.0
Debt/Equity0.0
ROA-15.6%
ROE-15.9%
Cash conversion1.4%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricPLRZActivity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity0.0%9.3% medp25 0.1% · p75 43.8%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 19:35 UTC#effe9f0c
Market quoteclose USD 15.77 · shares 0.00B diluted
no public URL
2026-05-04 04:50 UTC#424d6e56
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 00:12 UTCJob: 3e7dc6b3